



## July 2018 Newsletter

Volume 6 Issue 7

### A Letter from the Founder, Dr. Christine Brezden-Masley

Thank you for your continued support of the website and use of the e-referral clinical trial portal.

The CCTC continues to grow across Ontario with over 285 members across 31 institutions.

Our main goal is to showcase as many oncology clinical trials that are open in the province, providing ready access for your patients.

Simply send us an email with any suggestions you may have, so that we can continue to improve the service of the CCTC.

Sincerely,

Dr. Christine Brezden-Masley

### A Letter from the Project Manager, Alexandra Moskalewicz

Please feel free to share this newsletter with your colleagues in oncology, as we are always happy new members join the network!

As well, please contact me at [comettrials@smh.ca](mailto:comettrials@smh.ca) if I can be of any assistance in posting any new trials, or removing those from the website that have now closed to accrual at your centre.

Kind Regards,

Alexandra Moskalewicz

## ARTICLE RECOMMENDATION

### Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials

Basch, E., Dueck A.C, Rogak, L.  
[doi:10.1001/jamaoncol.2016.6749](https://doi.org/10.1001/jamaoncol.2016.6749) Published August 2017

**Importance:** In cancer clinical trials, symptomatic adverse events (AEs), such as nausea, are reported by investigators rather than by patients. There is increasing interest to collect symptomatic AE data via patient-reported outcome (PRO) questionnaires, but it is unclear whether it is feasible to implement this approach in multicenter trials.

**Objective:** To examine whether patients are willing and able to report their symptomatic AEs in multicenter trials.

**Findings:** Among 285 patients enrolled in 9 US multicenter cancer treatment trials, symptomatic adverse events were successfully self-reported by patients at 93.9% of expected times. Most patients believed that the system was easy to use and useful, and investigators thought that the patient-reported adverse event data were useful and accurate.

**Conclusion:** Participants in multicenter cancer trials are willing and able to report their own symptomatic AEs at most clinic visits and report more AEs than investigators. This approach may improve the precision of AE reporting in cancer trials.

## TRIALS SNAPSHOT

Trial Type	Any Malignancy	Breast	CNS	GI	GU	GYN	Head & Neck	Heme	Lung	Mel	Skin	Total
Imaging Study		1	1		1							3
Observational	1	3				1		1				6
Prevention				1				1				2
Radiation	1	2		3	6		1		6			19
Supportive Care	1	5										6
Surgical Therapy		1			1	1	1					4
Systemic Therapy	2	7		16	16	4	3	10	8	3	1	70
Therapeutic					2			2				4
<b>TOTAL</b>	<b>5</b>	<b>19</b>	<b>1</b>	<b>20</b>	<b>26</b>	<b>6</b>	<b>5</b>	<b>14</b>	<b>14</b>	<b>3</b>	<b>1</b>	<b>114</b>



## July 2018 Newsletter

Volume 6 Issue 7

### TRIALS OF THE MONTH

Type	Acronym	Study Title	Description	Site(s)
Breast	<a href="#">MAC.18/ POSITIVE</a>	A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy	<ul style="list-style-type: none"> <li>• Stage I—III ER +ve Breast Cancer</li> </ul>	Odette Cancer Centre
GU	<a href="#">IMvigor010</a>	A Phase Iii, Open-Label, Multicenter, Randomized Study Of Atezolizumab (Anti-Pd-L1 Antibody) Versus Observation As Adjuvant Therapy In Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection (Wo29636)	<ul style="list-style-type: none"> <li>• Adjuvant Systemic Therapy</li> <li>• Urothelial Carcinoma</li> </ul>	Odette Cancer Centre
Heme	<a href="#">Incyte Cita-del 203</a>	A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3K $\delta$ Inhibitor, in Relapsed or Refractory Follicular Lymphoma	<ul style="list-style-type: none"> <li>• Follicular Lymphoma</li> <li>• Systemic Therapy</li> </ul>	Odette Cancer Centre
Melanoma	<a href="#">IND.224</a>	A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of Patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases	<ul style="list-style-type: none"> <li>• Systemic Therapy</li> <li>• BRAF Mutation-Positive</li> </ul>	Odette Cancer Centre
Lung	<a href="#">BMS CheckMate 384</a>	A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks	<ul style="list-style-type: none"> <li>• Advanced or Metastatic NSCLC</li> <li>• Systemic Therapy</li> </ul>	Southlake Regional Health Centre
Any Malignancy	<a href="#">SC24</a>	A Randomized Phase II/III Study Comparing Stereotactic Body Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) for Patients With Spinal Metastases	<ul style="list-style-type: none"> <li>• Radiation Therapy</li> <li>• Bone Metastases</li> </ul>	London Health Sciences Centre
GI	<a href="#">IND.223</a>	A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer	<ul style="list-style-type: none"> <li>• Systemic Therapy</li> <li>• Metastatic Prostate Cancer</li> </ul>	London Health Sciences Centre



[Click here to NOMINATE your trial for Trials of the Month!](#)



## MEMBERSHIP UPDATES

**289 members**

**31 institutions**

**114 accruing trials**



## ACKNOWLEDGEMENTS

The CCTC has been funded by unrestricted educational grants from the following supporters:



## CONTACT US

Do you have any questions, feedback, suggestions? Please do not hesitate to contact us.

30 Bond Street  
Toronto, ON Canada  
M5B 1W8

[cometrials@smh.ca](mailto:cometrials@smh.ca)

(416) 809-3915

[www.cometrials.com](http://www.cometrials.com)

## INSTITUTIONS

Institution	Location	Members	Trials
Cambridge Memorial Hospital	Cambridge	3	3
Grand River Hospital	Waterloo	9	1
Humber River Regional Hospital	Toronto	5	2
Kingston General Hospital	Kingston	4	18
Juravinski Cancer Centre	Hamilton	7	-
Lakeridge Health Corporation	Oshawa	21	-
London Health Sciences Centre	London	11	60
Mackenzie Health Hospital	Richmond Hill	6	-
Markham Stouffville Hospital	Markham	4	1
Michael Garron Hospital	Toronto	7	
Mount Sinai Hospital	Toronto	2	2
North York General Hospital	Toronto	15	5
Odette Cancer Centre/Sunnybrook	Toronto	61	50
Ontario Institute for Cancer Research	Toronto	4	-
Ottawa Hospital	Ottawa	2	-
Princess Margaret Cancer Centre	Toronto	26	1
Quinte Health Care	Belleville	1	-
Rouge Valley Health System	Ajax	3	-
Royal Victoria Regional Health Centre	Barrie	24	16
Scarborough General Hospital	Toronto	3	-
Southlake Regional Health Centre	Newmarket	19	7
St. Joseph's Health Centre	Toronto	4	-
St. Joseph's Healthcare	Hamilton	4	-
St. Michael's Hospital	Toronto	14	3
Sudbury Regional Hospital	Sudbury	1	-
Thunder Bay Regional	Thunder Bay	2	-
Toronto General Hospital	Toronto	3	1
Trillium Health Partners	Mississauga	17	-
William Osler Health Systems	Brampton	4	-
Windsor Regional Hospital	Windsor	2	-
Wingham and District Hospital	Wingham	1	-